Avacta has a pre-clinical stage biopharmaceutical pipeline of Affimer therapeutic candidates for in-house and partnering programmes.

Our clinical focus is on Immuno-oncology (IO), for which we believe there are key benefits of Affimer technology.

The company has initiated its first internal programme targeting PD-L1 inhibition in order to rapidly progress the first Affimer therapeutic to the clinic and is also building a portfolio of antagonists and agonists aimed at more novel IO targets. See our current therapeutics pipeline below:

Avacta pipeline